Back to results
US 12,553,903 B2Granted
Ivaltinostat combination therapy for treating pancreatic cancer
AssigneeCG Pharmaceuticals, Inc
InventorsSangsook Cho, Joong Myung Cho
Life of this patent
Estimating the term…
Abstract
Embodiments of the present disclosure relates to ivaltinostat combination therapy for treating pancreatic cancer in subjects having low levels of serological protein biomarkers with negative correlation to progression-free survival (PFS).
Claims30
A method of treating pancreatic cancer in a subject in need thereof, comprising:
- receiving information on a subject's serological protein biomarker PECAM1 (CD31) expression level prior to the treatment;
- selecting the subject with a PECAM1 expression level of about 7.5 ng/ml or less;
- and
- administering an effective amount of ivaltinostat in combination with one or more additional anti-cancer agents to the subject.
1 more element
Dependencies are inferred from the claim text.